Loomis, Sayles & Company’s ResMed RMD Stock Holding History

Loomis, Sayles & Company’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-168	Closed	-$37K	–	1058
2023 Q1	$37K	Buy	168 +14	+9%	+$3.04K	﹤0.01%	668
2022 Q4	$32K	Buy	+154	New	+$33.8K	﹤0.01%	685
2021 Q4	–	Sell	-540	Closed	-$142K	–	879
2021 Q3	$142K	Hold	540	–	–	﹤0.01%	552
2021 Q2	$133K	Sell	540 -186	-26%	-$39.1K	﹤0.01%	548
2021 Q1	$141K	Hold	726	–	–	﹤0.01%	530
2020 Q4	$154K	Hold	726	–	–	﹤0.01%	509
2020 Q3	$124K	Sell	726 -79	-10%	-$14.6K	﹤0.01%	530
2020 Q2	$154K	Buy	805 +9	+1%	+$1.47K	﹤0.01%	506
2020 Q1	$117K	Sell	796 -401	-34%	-$63.9K	﹤0.01%	528
2019 Q4	$186K	Buy	1,197 +727	+155%	+$105K	﹤0.01%	533
2019 Q3	$64K	Buy	+470	New	+$61.6K	﹤0.01%	594
2016 Q1	–	Sell	-1,199	Closed	-$64K	–	1122
2015 Q4	$64K	Sell	1,199 -830	-41%	-$46.8K	﹤0.01%	730
2015 Q3	$103K	Buy	+2,029	New	+$109K	﹤0.01%	741

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Loomis, Sayles & Company's RMD Position: Q2 2023 in Review

Loomis, Sayles & Company sold out of ResMed (RMD) in Q2 2023, closing a stake of 168 shares — an estimated $37K sold.

Loomis, Sayles & Company first reported a position in RMD in Q3 2015 and held it in 13 quarters. The position peaked at $186K in Q4 2019. 731 funds tracked by Wall St. Rank hold RMD as of Q2 2023.

Loomis, Sayles & Company reported no remaining ResMed position as of Q2 2023 after selling out during the quarter.
Loomis, Sayles & Company sold 168 ResMed shares in Q2 2023, an estimated $37K.
Loomis, Sayles & Company first reported a position in ResMed in Q3 2015 and held it in 13 quarters.
Loomis, Sayles & Company's ResMed position peaked at $186K in Q4 2019.
731 funds tracked by Wall St. Rank held ResMed as of Q2 2023.

Based on Loomis, Sayles & Company's 13F filing for Q2 2023, filed 11 Aug 2023.